Natural killer (NK) T cells represent a unique T-cell population, which shares characteristic features with NK cells. Notably, both cell types surface express type II C-type lectin, NKR-P1B, and C (NK1.1) (3). In the mouse, the majority of NKT cells express an invariant T-cell receptor (TCR) ␣ chain encoded by V␣14 gene segments paired with J␣18 and a highly biased TCRV␤ toward V␤8.2, V␤7, and V␤2 (3) . The development of V␣14 ϩ NKT cells depends on CD1d, which is surface expressed together with ␤ 2 -microglobulin (␤2m) (3, 7, 39, 48) . The ␣-galactosylceramide (␣-GalCer), which is derived from a marine sponge, is recognized by all V␣14 ϩ NKT cells in the context of CD1d (29) , and microbial ligands have recently been identified (19, 31, 38) . The V␣14 ϩ NKT cells are abundant in the liver, where the majority of cells express CD4 and few cells lack both CD4 and CD8 (12) . Liver V␣14 ϩ NKT cells rapidly secrete high concentrations of both gamma interferon (IFN-␥) and interleukin-4 (IL-4) upon TCR ligation (12, 15, 16, 17) .
Listeria monocytogenes is a gram-positive facultative intracellular bacterium that preferentially replicates in macrophages and liver parenchymal cells (28) . Type I cytokines, notably IL-12 and IFN-␥, play a pivotal role in protection against experimental listeriosis of mice (1, 2, 26, 27, 41, 45, 54, 55, 57) , whereas type II cytokines such as IL-4 exacerbate disease (22, 50, 53, 56) . After systemic infection, the vast majority of L. monocytogenes organisms are rapidly trapped in the liver (34) . Hence, immunocompetent cells, which reside in the liver, are critical for the control of infection (20, 28) . Although sterile eradication of this pathogen is ultimately achieved by conventional T cells (28) , IFN-␥-secreting NK1.1 ϩ cells seem to participate in protection against L. monocytogenes infection (1, 2, 26, 28, 41, 45, 47, 55) .
We have previously shown that cells stained with monoclonal antibodies (MAbs) to CD4 and NK1.1 (CD4 ϩ NKT cells) become undetectable in the liver of mice after L. monocytogenes infection (17, 18) , which could be due to downmodulation of the NK1.1 marker upon activation (6, 44) . In the present study, we assessed NK1.1 expression on V␣14 ϩ NKT cells in the liver of mice at early stages of listeriosis by using ␣-GalCer-loaded CD1d (␣-GalCer/CD1d) tetramers. We found that during listeriosis, an ␣-GalCer/CD1d tetramer-reactive (␣-GalCer/CD1d ϩ ) NK1.1 Ϫ T-cell population developed from an NK1.1 ϩ subpopulation in a thymus-independent manner. These cells secreted IFN-␥ but not IL-4. We assume that this ␣-GalCer/CD1d ϩ NK1.1 Ϫ subset contributes to early antilisterial resistance, thus bridging the gap between early resistance mediated by professional phagocytes and subsequent acquired immunity mediated by conventional T cells. However, listeriosis was ameliorated in mice lacking ␣-GalCer/ CD1d ϩ T cells. It is possible that the NK1.1 ϩ subset, which produces IL-4 in addition to IFN-␥, is a detriment to the infected host and covers protective effects of the NK1.1 Ϫ subset, which exclusively produces IFN-␥.
MATERIALS AND METHODS
Mice. Female adult thymectomized (ATX, 8 weeks after birth) C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Breeding pairs of J␣18 Ϫ/Ϫ (29) and C57BL/6 V␤ a (V␤ a ) mice were kindly provided by M. Taniguchi (RIKEN Research Center for Allergy and Immunology, Yokohama, Japan) and A. M. Livingstone (Imperial College of Science, Technology, and Medicine, London, Great Britain), respectively. These mutants backcrossed onto C57BL/6 mice (J␣18 Ϫ/Ϫ and J␣18 ϩ/Ϫ , 8th generation; V␤ a , 18th generation), and C57BL/6 mice were maintained under specific-pathogen-free conditions, and weight-matched female mice were used at 8 to 12 weeks of age.
Antibodies. MAbs to TCR␣/␤ (H57-597), TCR␥/␦ (GL3), CD3ε (145-2C11), NK1.1 (PK136), CD4 (YTS.191.1), CD8␣ (YTS169.4), Fc␥ receptor (Fc␥R) (2.4G2), IL-12 (p40/p70) (C17.8), IL-4 (11B11, BVD6-24G2), and IFN-␥ (R4-6A2, XMG1.2) were purified from hybridoma culture supernatants. MAbs to IFN-␥ (XMG1.2) and IL-4 (BVD6-24G2) were biotinylated, and MAbs to TCR␣/␤ and CD3ε were conjugated with fluorescein isothiocyanate (FITC) by conventional methods. FITC-conjugated MAbs to CD11a (M17/4), CD54 (H9.2B8), CD25 (7D4), CD122 (TM-␤1), CD49d (R1-2), CD69 (H1.2F3), CD4 (H129.19), NK1.1 (PK136), and mouse immunoglobulin G2a (IgG2a; R19-15); biotinylated MAbs to NK1.1 (PK136), rat IgG2b (G15-337), and mouse IgG2a (R19-15); and biotinylated mouse IgG2a (G155-178) were purchased from BD PharMingen (Hamburg, Germany). Rabbit anti-asialo GM1 (ASGM1) antibody and rabbit IgG were obtained from Wako Chemicals (Neuss, Germany) and Sigma-Aldrich (Schnelldorf, Germany), respectively.
Bacteria and infection. L. monocytogenes (strain EGD) recovered from infected liver were grown in tryptic soy broth (Difco Laboratories, Detroit, MI) at 37°C for 18 h, and aliquots were frozen at Ϫ80°C until used. The final concentration of viable bacteria was enumerated by plate counts on tryptic soy agar (Difco). Mice were infected intravenously with 2 ϫ 10 3 L. monocytogenes. In vivo treatment. Mice were treated intraperitoneally (i.p.) with 1 g of recombinant IL-12 (rIL-12; Genzyme, Alzenau, Germany). To deplete NK1.1 ϩ cells, mice were treated i.p. with anti-NK1.1 MAb (300 g) 4 and 2 days before infection. For depletion of NK cells, mice were treated i.p. with anti-ASGM1 antibody (5 mg) 3 days before infection. To deplete CD4 ϩ cells, mice were treated i.p. with anti-CD4 MAb (300 g) 4 and 2 days before infection. Depletion of NK1.1 ϩ cells (Ͼ95%), NK cells (Ͼ95%), and CD4 ϩ cells (Ͼ98%) was verified by immunohistochemistry and/or flow cytometry. For endogenous IL-12 neutralization, mice were treated i.p. with anti-IL-12 MAb (500 g) 2 h before infection. Isotype-matched MAbs purified by the same procedure as for specific MAbs or phosphate-buffered saline (PBS) used for MAb purification were used as controls. Rabbit IgG served as a control for anti-ASGM1 antibody. Mouse CD1d/␤2m tetramer. Mouse CD1d/␤2m tetramers were prepared by using the baculovirus expression system using a CD1d construct with a BirA biotinylation site, followed by a His 6 tag as described previously (37) . In brief, Sf9 insect cell line (BD Biosciences, Heidelberg, Germany) was infected with mouse CD1d/␤2m-expressing virus stock kindly provided by M. Kronenberg (37) at a multiplicity of infection of 0.1 for expanding the viral stock. Culture supernatants were harvested on day 4 postinfection (p.i.) and used at high multiplicity of infection of 1 to 5. These large-scale cultures were performed in Sf-900 II serum-free medium (Gibco/Invitrogen Corp., Karlsruhe, Germany) and harvested on day 3 or 4 by centrifugation. Supernatants were concentrated by passing through a hollow-fiber tangential flow module (MiniKros 1,100 cm 2 ; Spectrum; MembraPure, Boddenheim, Germany). The CD1d molecules were purified by metal-chelating chromatography (Chelating Sepharose Fast Flow; Amersham Pharmacia Biotech, Uppsla, Sweden) on an NTA-Sepharose column (Amersham Pharmacia Biotech) charged with cobalt chloride (Roth, Karsruhe, Germany). Protein was eluted with 200 mM imidazole (Merck, Darmstadt, Germany), and pooled fractions were concentrated to 0.5 ml by ultrafiltration (Ultrafree units; Millipore, Bedford, MA). Purity and protein amount were assessed by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Bradford reagent (Bio-Rad, Munich, Germany), respectively. Purified CD1d protein was subsequently biotinylated with BirA enzyme (Avidity, Denver, CO) according to the manufacturer's instructions. Biotinylated CD1d proteins were purified by gel filtration (Superdex 200 HR10/30; Amersham Pharmacia Biotech). Soluble biotinylated CD1d/␤2m protein was loaded with or without ␣-GalCer (kindly provided by Kirin Brewery Co., Ltd., Tokyo, Japan), which was dissolved in PBS containing 0.5% Tween 20 at 220 g/ml at a molar ratio of 1:3 (protein-lipid) overnight at room temperature. For tetramerization, streptavidin (SA)-conjugated phycoerythrin (PE) (MobiTec, Göttingen, Germany) was added to ␣-GalCer/CD1d/␤2m monomers at a 1:4 (monomer-SA-conjugated PE) molar ratio. The purification of PE-labeled CD1d/␤2m tetramers loaded with or without ␣-GalCer was performed by gel filtration (Superdex 200 HR10/ 30; Amersham Pharmacia Biotek).
Cell preparation and flow cytometry. Mice were killed by cervical dislocation and organs were collected. Hepatic leukocytes (HLs) were prepared as described previously (15) . Bone marrow (BM) plugs in the femurs were eluted by flushing with RPMI 1640 containing 10% fetal calf serum (FCS). T cells were enriched by passage through a nylon wool column. Splenocytes were prepared by conventional methods. For staining with MAbs, cells were incubated with anti-Fc␥R MAb and then stained with conjugated MAbs at 4°C for 15 min. Biotinylated MAbs were visualized by using SA-conjugated CyChrome (BD PharMingen). Stained cells were washed with PBS containing 0.1% bovine serum albumin (Serva, Heidelberg, Germany) and 0.1% sodium azide (Merck, Darmstadt, Germany), fixed with 1% paraformaldehyde (Merck), and acquired by FACScan or FACSCalibur (BD Biosciences, Mountain View, CA), and lymphoid cells were analyzed with CellQuest software. For staining with ␣-GalCer/CD1d tetramer, cells were stained with PE-labeled ␣-GalCer/CD1d tetramers for 15 min at room temperature after blocking.
Determination of CFU. Mice were killed by cervical dislocation on day 4 p.i. The liver was perfused with 10 ml of sterile PBS to wash out bacteria in the blood vessels, and CFU counts in the liver were determined by plating serial dilutions of liver homogenates on tryptic soy agar plates.
Cell sorting. ␣-GalCer/CD1d ϩ cells were positively sorted by magnetic cell sorter (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. In brief, HLs were stained with PE-labeled ␣-GalCer/ CD1d tetramers for 15 min at room temperature after blocking and subsequently incubated with anti-PE microbeads (Miltenyi Biotec) at 6°C for 15 min. Cell suspensions were applied to an MSϩ/RSϩ column (Miltenyi Biotec), and then ␣-GalCer/CD1d ϩ cells were enriched. The purity of ␣-GalCer/CD1d ϩ cells was consistently Ͼ95%.
ELISPOT assay. IFN-␥ and IL-4 production was measured by the enzymelinked immunospot (ELISPOT) method as described previously (15, 17) with a slight modification. Briefly, cells were cultured for 18 h in the presence or absence of phorbol myristate acetate (PMA; 10 ng/ml; Sigma-Aldrich) and ionomycin (1 g/ml) in ELISPOT plates (Millipore, Eschborn, Germany) precoated with anti-IFN-␥ MAb (R4-6A2) or anti-IL-4 MAb (11B11). After being washed, the plates were incubated with biotinylated anti-IFN-␥ MAb (XMG1.2) or biotinylated anti-IL-4 MAb (BVD6-24G2), respectively. For developing spots, SAconjugated alkaline phosphatase (Dianova, Hamburg, Germany) and BCIP (5-bromo-4-chloro-3-indolylphosphate)-nitroblue tetrazolium tablets (SigmaAldrich) were used. The numbers of cytokine-secreting cells were estimated by counting spots using a dissecting microscope.
Statistical analysis. Statistical significance was determined by using a Student t test, and P values of Ͻ0.05 were regarded as significant.
RESULTS
Differential appearance of NK1.1 ؉ and NK1.1 ؊ subsets of ␣-GalCer/CD1d ؉ T cells in the liver after L. monocytogenes infection. C57BL/6 mice were infected with L. monocytogenes, and the kinetics of V␣14 ϩ T cells in the liver were monitored using ␣-GalCer/CD1d tetramers. High proportions of ␣-GalCer/CD1d ϩ T cells, as well as NK1.1 ϩ TCR␣/␤ cells, were detected in the liver before infection (Fig. 1A) . Consistent with recent findings (4), the majority of ␣-GalCer/CD1d ϩ T cells ϩ T cells, as well as NK1.1 ϩ TCR␣/␤ cells, were markedly reduced by day 2 p.i. and were still low on day 4 p.i. (Fig. 1A) . At these time points, only a few ␣-GalCer/ CD1d ϩ T cells coexpressed the NK1.1 marker. The numbers of HLs gradually increased after infection (Fig. 1B) . The absolute numbers of ␣-GalCer/CD1d ϩ NK1.1 ϩ T cells were markedly diminished by day 2 p.i., whereas the numbers of ␣-GalCer/CD1d ϩ NK1.1 Ϫ T cells increased subsequently, and the latter were dominant among the ␣-GalCer/ CD1d ϩ T-cell population on days 2 and 4 p.i. (Fig. 1C) . No inverse relationship was found in the appearance of NK1. is involved in the expansion of the ␣-GalCer/CD1d ϩ NK1.1 Ϫ T-cell subset. Consistent with previous findings (44), the absolute numbers of the ␣-GalCer/CD1d ϩ NK1.1 ϩ T-cell subset were markedly diminished by day 2 after rIL-12 treatment, whereas the NK1.1 Ϫ T-cell subset was virtually unaffected at this time point and expanded thereafter (Fig. 1D) . Consistent with this, anti-IL-12 MAb treatment reversed the reduction of the NK1.1 ϩ T-cell subset and the subsequent increase of the NK1.1 Ϫ T-cell subset of the ␣-GalCer/CD1d ϩ population during listeriosis (Fig. 2A) . Similar results were obtained in V␤ a mice (data not shown). Consistent with previous findings (54), the CFU counts in the liver were significantly, although slightly, reduced by anti-IL-12 MAb treatment (Fig. 2B) . Hence, IL-12 plays a critical role both in the reduction of the NK1.1 ϩ subset and in the subsequent increase of the NK1.1 Ϫ subset of the ␣-GalCer/CD1d ϩ T-cell population. (Fig. 3A) . Labeling with FITC-conjugated anti-mouse IgG2a MAb (secondary MAb for detection of anti-NK1.1 MAb) did not stain cells from MAb-treated mice, excluding the residual coating of the cells with MAb (data not shown). It is likely that some cells, which were slightly stained with anti-NK1.1 MAb, still remained in the liver even after anti-NK1.1 MAb treatment. This was probably caused by a biotin-mediated nonspecific reaction, because (i) similar staining patterns were obtained when cells were stained with biotinylated mouse IgG2a (isotype-matched MAb for anti-NK1.1 MAb; Fig. 3B ) and (ii) NK1.1 staining was completely negative when FITC-conjugated MAb to NK1.1 was used (Fig. 3C) . The increase in both the proportion and absolute numbers of ␣-GalCer/CD1d ϩ NK1.1 Ϫ T cells after L. monocytogenes infection was prevented by NK1.1 ϩ cell depletion ( Fig. 3A and D) , suggesting that NK1. ϩ T cells were virtually unaffected (Fig. 3E ). In contrast to anti-NK1.1 MAb treatment, both the proportion and the absolute number of ␣-GalCer/CD1d ϩ NK1.1 Ϫ T cells during listeriosis were increased by anti-ASGM1 antibody treatment ( Fig. 3E and F) . These results indicate that NK cells prevent the development of ␣-GalCer/CD1d ϩ NK1.1 Ϫ T cells in the livers of L. monocytogenes-infected mice. We conclude that the NK1.1 Ϫ T-cell subset, which appears in the L. monocytogenes-infected liver, is primarily derived from the NK1. ϩ T cells in the thymus and BM were determined. A small but distinct population of ␣-GalCer/CD1d ϩ T cells was detected in the BM, and the majority of these coexpressed NK1.1 (Fig. 4A) . In contrast, virtually all ␣-GalCer/CD1d ϩ T cells in the thymus coexpressed NK1.1 on their cell surface. Similar to the liver, ␣-GalCer/CD1d ϩ NK1.1 ϩ T cells in BM and thymus became virtually undetectable after anti-NK1.1 MAb treatment (Fig. 4A) . This was also true in other organs, including the spleen (data not shown). In parallel to the compression of the NK1.1 ϩ subset, the proportion of the NK1.1 Ϫ subset of ␣-GalCer/CD1d ϩ T cells increased in both organs after anti-NK1.1 MAb treatment (Fig. 4A) , although the absolute numbers remained virtually unchanged (data not shown). Slight staining with anti-NK1.1 MAb was due to a biotin-mediated nonspecific reaction (data not shown). Thus, anti-NK1.1 MAb treatment efficiently depleted ␣-GalCer/ CD1d ϩ NK1.1 ϩ T cells from the lymphoid organs. Similar to the liver, ␣-GalCer/CD1d ϩ NK1.1 ϩ T cells became virtually undetectable in the BM of L. monocytogenesinfected mice (Fig. 4B) . In contrast, in the thymus of L. monocytogenes-infected mice considerable numbers of the NK1.1 ϩ subset persisted, and the subset of ␣-GalCer/CD1d ϩ T cells did not enlarge. This discrepancy is probably due to differential IL-12 levels in different organs: high frequencies of IL-12-producing cells were detected in BM and liver during listeriosis, whereas IL-12 producers were virtually absent from the thymus (data not shown). Thus, thymic ␣-GalCer/CD1d ϩ
NK1.1 ϩ T cells were apparently unaffected by L. monocytogenes infection.
Thymus-independent emergence of ␣-GalCer/CD1d ؉ NK1.1 ؊ T cells. ATX mice were infected with L. monocytogenes, and the numbers of liver V␣14 ϩ T cells were determined by using ␣-GalCer/CD1d tetramers. Similar to euthymic mice, high numbers of ␣-GalCer/CD1d ϩ T cells were detected in the liver before infection, and the majority of these cells coexpressed NK1.1 (Fig. 5) . Absolute numbers of the NK1.1 ϩ subset were markedly diminished by day 4 p.i., whereas the NK1.1 Ϫ subset of ␣-GalCer/CD1d ϩ T cells was numerically increased (Fig. 5) . Thus, numerical alterations in the NK1.1 ϩ and NK1.1 Ϫ subsets of the ␣-GalCer/CD1d ϩ T-cell populations, in response to L. monocytogenes infection, were thymus independent.
Phenotypic changes of ␣-GalCer/CD1d ؉ T cells during listeriosis. We compared the surface expression of various markers on ␣-GalCer/CD1d ϩ T cells before and after L. monocytogenes infection. In uninfected mice, the vast majority of ␣-GalCer/ CD1d ϩ T cells expressed CD122 and high levels of CD11a, and this expression pattern remained unchanged during infection (data not shown). In contrast, CD69, CD54, CD25, and CD49d were upregulated after infection (Fig. 6) . These results suggest that ␣-GalCer/CD1d ϩ NK1.1 Ϫ T cells are highly activated. Similarly, we compared CD4 expression on ␣-GalCer/ CD1d ϩ T cells in the liver during listeriosis. Before infection, the majority (ϳ80%) of ␣-GalCer/CD1d ϩ T cells coexpressed CD4 and a minority (ϳ20%) lacked this marker (Fig. 7A) . In contrast, the percentages of CD4 ϩ and CD4 Ϫ cells among ␣-GalCer/CD1d ϩ T cells shifted to 65 and 35%, respectively, on day 4 p.i. Hence, L. monocytogenes infection primarily compressed the CD4 ϩ rather than CD4
؉ T cells lacking CD4, CD8, and NK1.1 during listeriosis. We previously reported that IL-4-secreting cells in the liver become virtually undetectable in parallel with the disappearance of CD4 ϩ NK1.1 ϩ T cells after L. monocytogenes infection (17, 18) . Because ␣-GalCer/CD1d ϩ NK1.1 Ϫ T cells, which developed in the liver after L. monocytogenes infection, are phenotypically different from the NK1.1 ϩ subpopulation that resides in naive mice, we wondered whether the NK1.1 Ϫ and NK1.1 ϩ subpopulations differ functionally. To address this issue, the ␣-GalCer/CD1d ϩ T cells were purified from the liver before and after infection, and IFN-␥ and IL-4 secretion were determined by ELISPOT assay. Substantial numbers of IFN-␥ and IL-4 producers were detected among ␣-GalCer/CD1d ϩ T cells from uninfected animals after in vitro stimulation with PMA and ionomycin (Fig. 7B) . Considerable numbers of IFN-␥ producers were found among ␣-GalCer/CD1d ϩ T cells from L. monocytogenes-infected mice, whereas IL-4-producing cells became virtually undetectable. These results suggest that ␣-GalCer/CD1d ϩ NK1.1 Ϫ T cells, which emerged in the L. monocytogenes-infected liver, fail to produce IL-4 and hence express a Th1-like phenotype.
The ␣-GalCer/CD1d ϩ T cells segregate into several subsets on the basis of CD4/NK1.1 surface expression. Moreover, the NK1. ϩ or NK1.1 ϩ cell depletion markedly reduced the numbers of IL-4-producing ␣-GalCer/CD1d ϩ T cells, whereas the numbers of IFN-␥ producers were comparable in both groups (Fig. 7B) . In contrast, after infection, the frequencies of IFN-␥-producing ␣-GalCer/CD1d ϩ T cells were 3.5-fold higher in CD4 ϩ cell-depleted mice compared to nondepleted mice. These results suggest that ␣-GalCer/CD1d ϩ NK1.1 Ϫ T cells in the L. monocytogenes-infected liver, which produce IFN-␥, are preferentially CD4 Ϫ 8 Ϫ . mice were infected with L. monocytogenes, and bacterial burdens were determined on day 4 p.i. Listerial CFU in both livers and spleens were significantly lower in J␣18 Ϫ/Ϫ mice than in J␣18 ϩ/Ϫ mice (Fig. 8) . Thus, J␣18 Ϫ/Ϫ mice were more resistant to L. monocytogenes infection than heterozygous littermates. These findings suggest that ␣-GalCer/CD1d ϩ T cells comprise a heterogeneous population, which in its entirety does not contribute to antilisterial protection and may even exacerbate disease. We consider it likely that the IFN-␥-producing NK1.1 Ϫ subset of ␣-GalCer/CD1d ϩ T cells ameliorates, while the IL-4-producing NK1.1 ϩ subset exacerbates, disease. ϩ subset in the periphery was recently found to be derived from a thymic NK1.1 Ϫ subpopulation of ␣-GalCer/ CD1d ϩ T cells (5) . In that study, NK1.1 surface expression on V␣14 ϩ T cells was acquired in the periphery after the cells had left the thymus during ontogeny. In our study, however, the NK1.1 Ϫ subset that emerged in the L. monocytogenes-infected liver developed from the NK1.1 ϩ subpopulation of ␣-GalCer/ CD1d ϩ T cells. Hence, the accumulation of V␣14 ϩ T cells in the liver is probably differentially regulated under physiological and under inflammatory conditions (10) .
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DISCUSSION
Expansion of V␣14 ϩ T cells in response to ␣-GalCer in vivo has been reported (8, 25, 58) . Because the numbers of NK cells were increased after L. monocytogenes infection (53) and the expansion of V␣14 ϩ T cells was severely impaired in the presence of NK cells (35, 46) , it is unlikely that the ␣-GalCer/ CD1d ϩ NK1.1 Ϫ T-cell population was expanded in situ. An increase of the ␣-GalCer/CD1d ϩ NK1.1 Ϫ T-cell population during listeriosis depended on IL-12. Hence, it is likely that stimulation by a specific antigen (␣-GalCer) and by the cytokine IL-12 have differential outcomes. Although we cannot formally exclude in situ expansion of V␣14 ϩ T cells, we consider the following scenario most likely. After having left the BM, ␣-GalCer/CD1d ϩ NK1.1 ϩ T cells encounter endogenous IL-12 at sites of inflammation, resulting in loss of the NK1.1 surface marker. (36, 49) . Differential stimulation, i.e., specific antigen versus IL-12, is probably responsible for distinct cytokine production with inflammation driving IFN-␥ production by V␣14 ϩ T cells (17, 18 ; the present study).
At first sight, the finding that listeriosis in V␣14 ϩ T-cell-deficient mice was ameliorated could be taken as an argument against a protective role of the V␣14 ϩ T cells in listeriosis. However, as shown here, two subsets of V␣14 ϩ T cells exist. (i) The first is the CD4 ϩ NK1.1 ϩ subset, which produces IL-4 and hence should be of no benefit or even be a detriment in listeriosis. At early stages of infection, exacerbation by this T-cell population seems to dominate because depletion of the total V␣14 ϩ T-cell population ameliorated listeriosis. This notion is consistent with previous findings showing that anti-CD1 MAb treatment improves listeriosis (51) . (ii) The CD4 Ϫ NK1.1 Ϫ subset produces IFN-␥, suggesting its beneficial role in listeriosis. The contribution of the NK1.1 Ϫ subset to resistance, however, occurs later and seems supportive but not essential, because conventional T cells can assume the burden of protection. These more subtle effects of V␣14 ϩ NK1.1 Ϫ T cells could not be visualized in mouse mutants devoid of the entire V␣14 ϩ T-cell population because gene knockout mutants only allow identification of essential phenotypic features of gene deletion. However, recent studies revealed a contribution of V␣14 ϩ T cells in protection against enteric listeriosis, suggesting a prevailing role of protective V␣14 ϩ T cells in mucosal defense (47) .
In conclusion, we show here the influences of bacterial infection on NK1.1 surface expression by V␣14 ϩ T cells. Although V␣14 ϩ T cells produce both IFN-␥ and IL-4 in naive mice, the majority of this cell population produces IFN-␥, but not IL-4, during listeriosis due to abundant IL-12 production. Therefore, it is tempting to assume that distinct V␣14 ϩ T-cell populations play unique roles in infection. Of these, the NK1.1 ϩ subset seems ineffectual or even harmful, whereas the NK1.1
Ϫ subset appears to contribute to antilisterial protection by means of IFN-␥, thus probably bridging the gap between early resistance and subsequent acquired immunity.
